Diabetic neuropathy: Molecular approach a treatment opportunity

Méndez-Morales, S.T.; Marco, J.C. Pérez-De; Rodríguez‐Cortés, Octavio; Flores-Mejía, Raúl; Martínez-Venegas, M.; Sánchez-Vera, Y.; Tamay‐Cach, Feliciano; Lomeli-Gonzaléz, J.; Reyes, Abraham; Lehman-Mendoza, R.; Martínez-Arredondo, H.A.; Vázquez-Dávila, Roberto Arturo; Torres-Roldan, J.F.; Correa‐Basurto, José; Arellano-Mendoza, Mónica Griselda

doi:10.1016/j.vph.2022.106954

Cited by 21 publications

(16 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the world, the number of DM patients had quadrupled in the past three decades, and meanwhile, DM was the ninth major cause of death, among which Asia had become the major area of the rapidly emerging T2DM global epidemic, and most T2DM patients always had at least one complication [ 23 ]. The complexity of T2DM treatment and care were very challenging because they involved the prevention of organ damage and complications [ 23 ], including chronic damage and dysfunction of various tissues, especially kidneys [ 4 ], blood vessels [ 5 ], nerves [ 6 ], and heart [ 7 ], among which kidney damage was one of the most common microvascular complications in DM patients, which brought great challenges to the treatment and nursing for DM patients.…”

Section: Discussionmentioning

confidence: 99%

“…In the world, the number of DM patients had quadrupled in the past three decades, and meanwhile, DM was the ninth major cause of death, among which Asia had become the major area of the rapidly emerging T2DM global epidemic, and most T2DM patients always had at least one complication [23]. The complexity of T2DM treatment and care were very challenging because they involved the prevention of organ damage and complications [23], including chronic damage and dysfunction of various tissues, especially kidneys [4], blood vessels [5], nerves [6], and heart [7], among SGLT-2 inhibitors were a group of antidiabetic drugs, which had the ability to reduce the blood sugar via inhibiting SGLT-2 [24]. Furthermore, except for lowering blood sugar [25][26][27][28][29][30], SGLT-2 inhibitors also had abilities to lose weight [24,31,32], reduce cardiovascular outcomes and mortality risk [33], and play renal protective effect [15].…”

Section: Discussionmentioning

confidence: 99%

“…What was more important was that DM could be complicated with multiple diseases significantly increasing the death risk of DM patient [ 1 ]. As everyone knows, long-term hyperglycemia would result in chronic damage and dysfunction of various tissues, especially kidneys [ 4 ], blood vessels [ 5 ], nerves [ 6 ], and heart [ 7 ], among which kidney damage was one of the most common microvascular complications in DM patients, which brought great challenges to the treatment and nursing for DM patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care

Wang

Zhang²,

Yang

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

Objectives. The purpose of this study was to explore the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on urine albumin to creatinine ratio (UACR) in type 2 diabetes mellitus (T2DM) patients and to recommend appropriate medication care scheme. Methods. 8371 T2DM patients from four dapagliflozin studies and two canagliflozin studies were collected for analyzing with nonlinear mixed effect model (NONMEM). The change rates of UACR from baseline were intended to be evaluation indicators. Results. In the present study, there was no significant difference in the effects on UACR using dapagliflozin or canagliflozin treatment in T2DM patients. The maximal effect ( E max ) and the treatment duration of reaching half of E max (ET50) from SGLT-2 inhibitors on UACR in T2DM patients were -19.2% and 0.448 weeks, respectively. Further, the treatment duration to reach 25%, 50%, 75%, and 80% E max was 0.150 weeks, 0.448 weeks, 1.344 weeks, and 1.792 weeks, respectively. Namely, for achieving the plateau period (80% of E max ) of SGLT-2 inhibitors on UACR in T2DM patients, 10 mg/day dapagliflozin (or 100 mg/day canagliflozin) should be taken for at least 1.792 weeks. Conclusions. To our knowledge, the present study explored the effects of SGLT-2 inhibitors on UACR in T2DM patients, meanwhile, recommended appropriate medication care scheme for the first time.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the world, the number of DM patients had quadrupled in the past three decades, and meanwhile, DM was the ninth major cause of death, among which Asia had become the major area of the rapidly emerging T2DM global epidemic, and most T2DM patients always had at least one complication [23]. The complexity of T2DM treatment and care were very challenging because they involved the prevention of organ damage and complications [23], including chronic damage and dysfunction of various tissues, especially kidneys [4], blood vessels [5], nerves [6], and heart [7], among SGLT-2 inhibitors were a group of antidiabetic drugs, which had the ability to reduce the blood sugar via inhibiting SGLT-2 [24]. Furthermore, except for lowering blood sugar [25][26][27][28][29][30], SGLT-2 inhibitors also had abilities to lose weight [24,31,32], reduce cardiovascular outcomes and mortality risk [33], and play renal protective effect [15].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care

Wang

Zhang²,

Yang

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia, which is caused by defective insulin secretion, impaired insulin biology, or both. Long-term hyperglycemia leads to chronic damage and dysfunction of various tissues, especially eyes ( Yao et al, 2022 ), kidneys ( Georgianos et al, 2022 ), heart ( Qiu et al, 2022 ), blood vessels ( Li et al, 2016 ), and nerves ( Mendez-Morales et al, 2022 ). In 2010, the estimated prevalence of DM in adults worldwide was 6.4%, and it will probably rise up to 7.7% by 2030 ( Shaw et al, 2010 ; Margaritis et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients

Wang

Zhang²,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Dapagliflozin has been used to treat patients with type 1 diabetes mellitus; however, the actual drug efficacy of dapagliflozin on glycated hemoglobin (HbA1c) and whether there is a rebound from dapagliflozin efficacy on HbA1c remain unknown. The present study aimed to explore the actual therapeutic effect and rebound situation of dapagliflozin on HbA1c in type 1 diabetes mellitus patients. A total of 1,594 type 1 diabetes mellitus patients were enrolled for analysis using a non-linear mixed effect model from randomized controlled trials from published literature works including two 5 mg/day dapagliflozin dosage groups and three 10 mg/day dapagliflozin dosage groups. The change rate of HbA1c from a baseline value was chosen as a dapagliflozin pharmacodynamic evaluation index. After deducting control group effects, the therapeutic effect of 5 and 10 mg/day dapagliflozin on HbA1c in type 1 diabetes mellitus patients had no significant difference. In addition, the actual maximal efficacy (AEmax) of dapagliflozin on HbA1c was -6.24% at week 9. When it reached the AEmax, the dapagliflozin pharmacodynamic rebound on HbA1c occurred, and when the treatment was continued for 0.5 and 1 year, the actual efficacies were -4.70% (75% AEmax) and -3.27% (52% AEmax), respectively. This was the first time to clarify the actual therapeutic effect and rebound situation of dapagliflozin on HbA1c in type 1 diabetes mellitus patients, providing a reference value for clinical practices.

show abstract

“…It has been well established that visceral adipose tissue (VAT) can overproduce several bioactive pro-inflammatory cytokines and adipocytokines that lead to IR, metabolic disorders, chronic inflammation, oxidative stress, endothelial dysfunction, and atherosclerotic vascular damage, subsequently resulting in nerve ischemia and direct axonal injury. 5,[8][9][10][11] Obesity is usually measured using several indicators such as body mass index (BMI), waist circumference (WC), waist-to-hip ratio, and body fat mass, however, these indicators are unable to accurately distinguish between VAT and subcutaneous adipose tissue. 12 At present, although magnetic resonance imaging (MRI) and computed tomography (CT) are the gold standard to directly measure VAT, these techniques are not feasible because of consuming time, expense, and radioactivity.…”

Section: Introductionmentioning

confidence: 99%

Lower Visceral Fat Area in Patients with Type 2 Diabetic Peripheral Neuropathy

Wu¹,

Wan²,

Xu³

et al. 2022

DMSO

View full text Add to dashboard Cite

There is preliminary evidence that visceral fat area (VFA) was associated with the presence of type 2 diabetic peripheral neuropathy (DPN) in the Korean population; however, no studies have reported the association in Chinese population. The purpose of this study was to explore the possible correlation of VFA with DPN in such a population. Methods: A total of 2498 hospitalized patients with type 2 diabetes mellitus (T2DM) undergone VFA measurement, and were divided into DPN group (n=900) and non-DPN group (n=1594). The association of VFA with the presence of DPN was evaluated by correlation and multiple logistic regression analyses, generalized additive model with a smooth curve fitting, and receiver operating characteristic (ROC) curve analysis. Results:The VFA was significantly lower in the DPN group than in the non-DPN group (P < 0.001). VFA was significantly and positively associated with sural nerve conduction velocity (SNCV) and amplitude potential (SNAP) and negatively associated with the presence of DPN (all P< 0.001); there was no significant difference in the curve fitting (P = 0.344). Multivariate logistic regression analysis showed that the risk of presence of DPN decreased progressively across the VFA quartiles (P for trend < 0.001) and was significantly lower in patients in the highest VFA quartile than in those in the lowest quartile (OR: 0.382, 95% CI 0.151-0.968, P< 0.001) after multivariate adjustment. The ROC analysis revealed that the best cut-off value of VFA for predicting the presence of DPN was 50.5cm 2 (sensitivity 84.40%; specificity 34.00%). Conclusion: These results suggest that lower VFA level may be associated with increased risk of the presence of DPN in T2DM patients.

show abstract

Diabetic neuropathy: Molecular approach a treatment opportunity

Cited by 21 publications

References 71 publications

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients

Lower Visceral Fat Area in Patients with Type 2 Diabetic Peripheral Neuropathy

Contact Info

Product

Resources

About